GSK Reports Positive Phase 3 Data For Meningococcal Vaccine Candidate

By Michael Susin

GSK PLC said Tuesday that data from a Phase 3 study showed that its vaccine candidate against the bacteria that causes meningitis and septicaemia has met all primary endpoints.

The pharmaceutical giant said its MenABCWY five-in-one combination vaccine candidate showed a clinically meaningful immune response and was well tolerated.

If approved, the vaccine candidate could provide the broadest meningococcal serogroup coverage and could lead to a simplified immunization schedule, it added.

GSK said it is working closely with regulators to review the data and the detailed results will be presented in a publication.

Invasive meningococcal disease, a major cause of meningitis and septicaemia, is an uncommon but serious illness that can cause life-threatening complications or even death, typically amongst previously healthy children and adolescents, it said.

Write to Michael Susin at [e-mail]

(END) Dow Jones Newswires

March 14, 2023 03:38 ET (07:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.